Intellia Therapeutics, Inc. $NTLA Stake Decreased by Interchange Capital Partners LLC

Interchange Capital Partners LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,665 shares of the company’s stock after selling 1,202 shares during the quarter. Interchange Capital Partners LLC’s holdings in Intellia Therapeutics were worth $100,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. HighTower Advisors LLC raised its position in shares of Intellia Therapeutics by 8.2% during the 1st quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock worth $120,000 after buying an additional 1,282 shares in the last quarter. Harbour Investments Inc. raised its position in shares of Intellia Therapeutics by 27.2% during the 2nd quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock worth $62,000 after buying an additional 1,419 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after buying an additional 1,655 shares in the last quarter. Arete Wealth Advisors LLC raised its position in shares of Intellia Therapeutics by 21.8% during the 1st quarter. Arete Wealth Advisors LLC now owns 12,512 shares of the company’s stock worth $89,000 after buying an additional 2,240 shares in the last quarter. Finally, LMG Wealth Partners LLC boosted its stake in Intellia Therapeutics by 28.4% during the first quarter. LMG Wealth Partners LLC now owns 14,285 shares of the company’s stock valued at $102,000 after buying an additional 3,157 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Activity at Intellia Therapeutics

In other news, Director William J. Chase bought 100,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the transaction, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on NTLA shares. Guggenheim reaffirmed a “buy” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Saturday. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. HC Wainwright upped their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 19th. Finally, Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 6th. Thirteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $28.47.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $25.60 on Monday. The firm’s 50 day simple moving average is $16.82 and its 200-day simple moving average is $12.13. The company has a market cap of $2.75 billion, a P/E ratio of -5.46 and a beta of 2.37. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm’s quarterly revenue was up 104.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.52) earnings per share. On average, analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.